About the Summit
Join us and the VPs, Heads, and Directors of Translational Oncology, Target Discovery, and Early Drug Development to discuss how to develop novel inhibitors of specific DNA repair enzymes that can be used as either monotherapy or in combination with other agents within predictable, identifiable, DDR-defective tumor populations.
Furthermore, there will be a unique pre-conference focus day looking at the rationales and approaches for enhancing replication catastrophe in cancerous cells and inhibiting DNA repair mechanisms which prevent apoptosis.
This is your opportunity to reconnect with your peers from industry and academia at a time when meeting is more difficult than ever to discuss key topics including:
Gain Unique Insights into the Key Issues Facing the Industry
Assessing the Potential of PARP Inhibitors in Combination Therapies to Overcome Resistance Mechanisms
Analyzing the Opportunities to Increase Therapeutic Index
Identifying the Biomarkers of Response
ATR and Targeted Replication Stress
Next Generation Synthetic Lethal Interactions